A physician and a lawyer argue against a dermatology clinic switching from a small, reliable pathology lab to a large-scale pathology lab in order to receive volume discounts and increase profit.
Stanford University Medical School established a positive partnership with a pharmaceutical company to offer an industry-sponsored resident elective course in a way that minimizes conflict of interest and has been accepted by the ACGME.
Two physicians give an overview of the iPledge program and discuss the problematic aspects of the program for physicians who prescribe isotretinoin and their patients.
A physician argues that pharmaceutical industry support for residency programs creates a conflict of interest and compromises the educational integrity of the programs.
Physicians should prescribe the best course of treatment for their cancer patients, even if the proposed treatment falls within the experimental treatment clauses in health insurance coverage.
Physicians should ensure that overwhelmed young patients receive the psychological support they need, especially when recommending optional treatments following the grueling main treatment for breast cancer.